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Abstract
Accurate risk stratification is key to reducing cancer morbidity through targeted screening
and preventative interventions. Numerous breast cancer risk prediction models have been
developed, but they often give predictions with conflicting clinical implications. Integrating
information from different models may improve the accuracy of risk predictions, which would
be valuable for both clinicians and patients. BRCAPRO and BCRAT are two widely used
models based on largely complementary sets of risk factors. BRCAPRO is a Bayesian model
that uses detailed family history information to estimate the probability of carrying a BRCA1/2
mutation, as well as future risk of breast and ovarian cancer, based on mutation prevalence
and penetrance (age-specific probability of developing cancer given genotype). BCRAT uses a
relative hazard model based on first-degree family history and non-genetic risk factors. We
consider two approaches for combining BRCAPRO and BCRAT: 1) modifying the penetrance
functions in BRCAPRO using relative hazard estimates from BCRAT, and 2) training an
ensemble model that takes as input BRCAPRO and BCRAT predictions. We show that the
combination models achieve performance gains over BRCAPRO and BCRAT in simulations
and data from the Cancer Genetics Network.
1 Introduction
Breast cancer is the second most common cancer and the second leading cause of cancer death
in women in the U.S [1, 2]. Identifying individuals at high risk is critical for guiding decisions
about risk management and prevention, including screening, genetic counseling and testing, and
preventative procedures. In clinical practice, at least 24 breast cancer risk prediction models
have been developed to help identify higher risk individuals [3]. These models estimate an
individual’s risk of carrying a pathogenic mutation in a breast cancer susceptibility gene and/or
an individual’s future risk of breast cancer, and they are based on a wide range of risk factors,
methodologies, and study populations. Some models, such as the Breast Cancer Risk Assessment
Tool (BCRAT) [4, 5, 6, 7], are regression-based models that use hormonal/reproductive risk
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factors (such as age at first live birth) and simple summaries of family history. Others, such as
BRCAPRO [8], BOADICEA [9, 10, 11], and IBIS [12], use detailed family history information and
principles of genetic inheritance. IBIS and BOADICEA [11] also take into account non-genetic
risk factors. Different models can output risk predictions with conflicting treatment implications
[13, 14]. One solution is to select a single model upon which to base intervention decisions [15, 16].
However, identifying the best model for a given patient can be difficult, and, even if such a
model is identified, other models could still contribute additional relevant information. Thus,
it is important to systematically integrate information from different models to achieve more
comprehensive and accurate risk assessment.
We investigate methods for combining BRCAPRO [8] and BCRAT [4, 5, 6, 7], two widely
used and validated [17, 18, 19, 20, 21, 22] breast cancer risk prediction models based on different
approaches and risk factors. BRCAPRO is a family history-based model that provides carrier
probabilities for breast cancer susceptibility genes BRCA1 and BRCA2 as well as future risk
estimates for invasive breast cancer and for ovarian cancer. It translates family history data into
risk estimates using Mendelian laws of inheritance, Bayes’ rule, and literature-based estimates
of mutation prevalence and penetrance (age-specific probability of developing cancer given
genotype). BCRAT estimates an individual’s future risk of invasive breast cancer based on a
relative hazard model that includes age, hormonal and reproductive risk factors, breast biopsy
history, and first-degree family history of breast cancer. The model was originally developed
using case-control data from Caucasian women participating in a U.S. mammography screening
program and was later updated for African-American [5], Asian-American [6], and Hispanic [7]
women.
Although there is some overlap in the inputs to BRCAPRO and BCRAT, the two models are
largely complementary (Figure 1). BRCAPRO uses extensive family history information while
BCRAT considers only first-degree relatives. BCRAT considers several non-genetic risk factors
that are not considered by BRCAPRO, including age at menarche, age at first live birth, and breast
biopsies. A validation study in a large U.S. screening cohort found that 6-year risk predictions
from BRCAPRO and BCRAT had a moderate correlation of 0.53 [22]. Since BRCAPRO and BCRAT
embed different information, combining these models could potentially lead to accuracy gains.
There already exist hybrid models that incorporate both detailed family history information
and non-genetic risk factors: IBIS [12] and BOADICEA [11]. However, we believe it is valuable to
investigate the combination of BRCAPRO and BCRAT because it will allow us to determine 1)
how much predictive value non-genetic risk factors add to BRCAPRO and how much predictive
value detailed family history adds to BCRAT, and 2) whether model combination can achieve
competitive performance compared to developing a new hybrid model from the ground up.
We consider two combination approaches: 1) penetrance modification and 2) training an
ensemble model. The first approach involves modifying the penetrance functions in BRCAPRO to
account for the effects of the BCRAT risk factors. We develop a penetrance modification model,
BRCAPRO+BCRAT (M), using a relative hazard approach [23] that has similarities to the one used
in IBIS.
Ensemble learning consists of training multiple base models and combining their predictions.
A wide variety of ensemble methods have been developed, including stacking [24], which involves
training a meta-model to optimally combine predictions from the base models, bagging [25, 26],
which involves averaging models trained on bootstrap samples of the original data, and boosting
[27], which involves constructing an ensemble by sequentially adding new models that are trained
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Figure 1: Inputs to BRCAPRO and BCRAT.
to correct the errors of previous ones. There is extensive literature, both empirical [28, 29] and
theoretical [30, 31, 32, 33, 34], showing that ensembles can achieve performance gains over their
base models, especially when the base models produce dissimilar predictions [35, 36]. In many
settings, ensemble models perform well because averaging reduces variance and can expand
the set of functions that can be represented by the base models [37]. Debray et al. (2014) [38]
demonstrated the value of aggregating published prediction models using real and simulated data
on deep venous thrombosis and traumatic brain injury. Across various scenarios, model averaging
and stacking outperformed model re-calibration [39, 40] and performed as well as or better than
developing a new model from scratch. Moreover, the authors noted that stacking is more efficient
than model averaging since stacking has fewer unknown parameters. In the setting of breast
cancer risk prediction, Ming et al. (2019) [41] showed that boosting and random forest, which is a
form of bagging, were able to achieve higher discriminatory accuracy compared to BCRAT and
BOADICEA. In this paper, we develop a stacked logistic regression ensemble, BRCAPRO+BCRAT
(E), that takes as input predictions from BRCAPRO and BCRAT.
We compare the performance of the combination models to the individual BRCAPRO and
BCRAT models in simulations and a data application, where we use training data from the
Newton-Wellesley Hospital (NWH) and validation data from the Cancer Genetics Network (CGN).
In the data application, we also use IBIS as a reference for comparison to evaluate the relative
performance of combining existing models versus developing a hybrid model from the ground
up.
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2 Methods
2.1 General Notation
Given a female proband (individual who presents for risk assessment) without a previous
diagnosis of breast cancer, the goal is to predict her risk of developing invasive breast cancer
within τ years based on family history H (described in Section 2.2.1) and other risk factors X
(described in Section 2.2.2) while accounting for death from other causes as a competing risk. τ is
a pre-specified positive integer.
Let a˜ be the proband’s current age, T˜B the age at onset of breast cancer, T˜D the age at death
from other causes, and T˜ = min(T˜B, T˜D) the time to the first event (either breast cancer or death),
with a˜, T˜B, T˜D, and T˜ taking on continuous values in the interval [0,∞). Let a = ba˜c, TB = bT˜Bc,
TD = bT˜Dc, and T = bT˜c, where b·c denotes the floor function. a, TB, TD, and T are discrete
versions of a˜, T˜B, T˜D, and T˜ observed at yearly intervals. Let J denote the type of the first event,
with J = B if T˜B ≤ T˜D and J = D otherwise.
BRCAPRO uses a discrete model for T while BCRAT and IBIS use continuous models for
T˜. We will use discrete T for the penetrance modification model (since it is an extension of
BRCAPRO). For the ensemble model, time can be treated as either continuous or discrete. Without
loss of generality, we will use continuous time notation.
2.2 Existing Models
2.2.1 BRCAPRO
BRCAPRO [8] estimates the probability of carrying a deleterious germline mutation in BRCA1 and
BRCA2 using Bayes’ rule, laws of Mendelian inheritance, mutation prevalence and penetrance,
and family history. It also estimates future risk of breast and ovarian cancer based on the carrier
probabilities and penetrances.
Family history can be represented as a pedigree, or a graph where each node is a family
member and edges flow from parents to offspring. Let R be the number of relatives in the
pedigree besides the proband and let r = 0, 1, . . . , R index the family members, where r = 0
corresponds to the proband. For each family member r, let Hr be a vector containing the following
information on demographics and breast/ovarian cancer history: current age or age at death,
gender, race/ethnicity, relation to the proband, breast cancer status, age at breast cancer diagnosis
if affected, ovarian cancer status, age at ovarian cancer diagnosis if affected, genetic testing
results if available, whether the individual has had a prophylactic mastectomy, mastectomy age if
applicable, whether the individual has had a prophylactic oophorectomy, and oophorectomy age
if applicable. Let H = (H0, . . . , HR).
Additionally, let Γr be family member r’s BRCA1/BRCA2 genotype, with Γr = 0 if r is a
non-carrier, Γr = 1 if r is a carrier of a mutation in BRCA1 only, Γr = 2 if r is a carrier of a
mutation in BRCA2 only, and Γr = 3 if r is a carrier of mutations in both BRCA1 and BRCA2.
Using Bayes’ rule and the assumption of conditional independence of phenotypes given
genotypes (across individuals as well as cancer types), the proband’s probability of having
genotype Γ0 is
P(Γ0|H) =
P(Γ0)∑Γ1,...,ΓR ∏
R
r=0 P(Hr|Γr)P(Γ1, . . . , ΓR|Γ0)
∑Γ0 P(Γ0)∑Γ1,...,ΓR ∏
R
r=0 P(Hr|Γr)P(Γ1, . . . , ΓR|Γ0)
. (1)
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The summation over genotypes is calculated using the Elston-Stewart peeling algorithm [42] and
P(Γ1, . . . , ΓR|Γ0) is calculated based on Mendelian laws of inheritance. The prevalences P(Γ0) are
obtained from the literature and are ethnicity-specific (in particular, different prevalences are
used for Ashkenazi Jewish and non-Ashkenazi Jewish individuals). P(Hr|Γr) is calculated using
literature-based penetrances for breast and ovarian cancer. The penetrances are functions of age
and are cancer- and sex-specific. The penetrance functions for non-carriers are based on rates from
the Surveillance, Epidemiology, and End Results (SEER) program and are race-specific, while the
penetrance functions for carriers are from a meta-analysis of published studies [43].
After estimating the carrier probabilities, BRCAPRO calculates future risk of breast and ovarian
cancer through a weighted average of the genotype-specific risks. To simplify the notation, from
here on we will omit the subscript 0 from Γ0 (throughout the rest of the paper, we only refer to
the proband’s genotype and not the genotypes of the other family members). The proband’s risk
of developing breast cancer between ages a and a + τ, conditional on having genotype γ and not
having breast cancer by age a, is
P(T ≤ a + τ, J = B|T > a, Γ = γ) =
a+τ
∑
t=a+1
P(T = t, J = B|T ≥ t, Γ = γ)P(T ≥ t|Γ = γ)
P(T > a|Γ = γ)
=
a+τ
∑
t=a+1
λ
γ
B(t)
t−1
∏
u=a+1
(
1− λγB(u)− λD(u)
)
(2)
where λγB(t) = P(T = t, J = B|T ≥ t, Γ = γ) is the cause-specific hazard of breast cancer
conditional on genotype g and λD(t) = P(T = t, J = D|T ≥ t) is the cause-specific hazard of
death from causes other than breast cancer. λγB(t) is calculated from the female breast cancer
penetrance for genotype g, P(T = t, J = B|Γ = γ), using the recursive formula
λ
γ
B(t) =
P(T = t, J = B|Γ = γ)
∏t−1u=1(1− λγB(u)− λD(u))
, (3)
while λD(t) is estimated based on SEER mortality rates for all causes except breast cancer.
The final risk estimate is
P(T ≤ a + τ, J = B|T > a, H) =
3
∑
γ=0
P(T ≤ a + τ, J = B|T > a, Γ = γ)P(Γ = γ|H). (4)
Software for running BRCAPRO is available through the BayesMendel R package [44]. We
used v2.1-6.1 (selecting the crude risk option).
2.2.2 BCRAT
BCRAT [4, 5, 7, 6] estimates the relative hazard of developing breast cancer based on age (di-
chotomized into < 50 and ≥ 50) and the following risk factors: X1 = age at menarche, X2 = number
of benign breast biopsies, X3 = age at first live birth (if nulliparous, set X3 = 25), X4 = number of
female first-degree relatives with breast cancer, and X5 = presence of atypical hyperplasia (0, 1, or
unknown). Let X = (X1, . . . , X5).
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The relative hazard for an individual of age t with risk factors X compared to an individual of
age t with no BCRAT risk factors (other than age) is
r(t, X) = exp(β1 I[X1 ∈ [12, 13]] + β2 I[X1 < 12]+
β3 I[X2 = 1] + β4 I[X2 ≥ 2] + β5 I[t ≥ 50]I[X2 = 1] + β6 I[t ≥ 50]I[X2 ≥ 1]+
β7 I[X3 ∈ [20, 24]] + β8 I[X3 ∈ [25, 29]] + β9 I[X3 > 29]+
β10 I[X4 = 1] + β11 I[X4 = 2]+
β12 I[X3 ∈ [20, 24]]I[X4 = 1] + β13 I[X3 ∈ [25, 29]]I[X4 = 1] + β14 I[X3 > 29]I[X4 = 1]+
β15 I[X3 ∈ [20, 24]]I[X4 ≥ 2] + β16 I[X3 ∈ [25, 29]]I[X4 ≥ 2] + β17 I[X3 > 29]I[X4 ≥ 2]+
β18 I[X2 > 0]I[X5 = 0] + β19 I[X2 > 0]I[X5 = 1]), (5)
where I[·] denotes the indicator function (equal to 1 if the bracketed expression is true and 0
otherwise). The relative hazard model includes interactions between age and number of biopsies,
as well as age at first live birth and number of affected relatives. The regression coefficients
were estimated from U.S. case-control studies. Separate models were fit to data from white,
African-American, Asian, and Hispanic women to obtain race-specific estimates.
The risk of developing breast cancer between ages a˜ and a˜ + τ, conditional on not having
breast cancer at age a˜, is
P(T˜ ≤ a˜ + τ, J = B|T˜ > a˜, X) =
∫ a˜+τ
a˜
λ˜B,0(t)r(t, X) exp
{
−
∫ t
a˜
(λ˜B,0(u)r(u, X) + λ˜D(u))du
}
dt,
(6)
where λ˜B,0(t) = lim
dt→0
P(t ≤ T˜ < t+ dt, J = B|T˜ ≥ t, X = 0)/dt is the cause-specific hazard of breast
cancer for those with no BCRAT risk factors and λ˜D(u)) = lim
dt→0
P(t ≤ T˜ < t+ dt, J = D|T˜ ≥ t)/dt
is the cause-specific hazard of death from causes other than breast cancer. λ˜B,0(t) is calculated
from λ˜B(t) = lim
dt→0
P(t ≤ T˜ < t + dt, J = B|T˜ ≥ t)/dt, the cause-specific hazard of breast cancer in
the general population, using the formula (see [4])
λ˜B,0(t) = λ˜B(t)(1− AR(t)), (7)
where, letting P(X|t) be distribution of X for age t,
AR(t) = 1− 1
∑X r(t, X)P(X|t)
, (8)
is the population attributable risk due to X for those of age t. P(X|t) and r(t, X) are both assumed
to be constant for t < 50 and for t ≥ 50, so AR(t) is as well. Race-specific estimates of λ˜B(t) and
AR(t) are obtained from SEER data and λ˜D(t) is estimated based on SEER mortality rates for all
causes except breast cancer. In the implementation of the model, the age scale is divided into
13 intervals and λ˜B(t) and λ˜D(t) are assumed to be constant on each interval (see [4] for more
details).
Software for running BCRAT is available through the BCRA R package (https://cran.
r-project.org/web/packages/BCRA/index.html). We used version 2.1.
2.2.3 IBIS
In our data application, we also use the IBIS model [12, 45] as a reference for comparison since
it combines detailed family history information with non-genetic risk factors. It first calculates
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carrier probabilities and risk of breast cancer based on family history, then incorporates additional
risk factors Y (age at menarche, age at menopause, height, body mass index, age at first live
birth, menopausal hormone therapy, atypical hyperplasia, lobular carcinoma in situ (LCIS), breast
density, and SNPs) via a relative hazard model. The carrier probabilities are calculated using
a similar approach as in BRCAPRO, but in addition to BRCA1 and BRCA2, IBIS considers a
hypothetical low-penetrance susceptibility gene that acts as a surrogate for all other breast cancer
susceptibility genes. The prevalence and penetrance of BRCA1 and BRCA2 are obtained from the
literature and the prevalence and penetrance of the hypothetical gene are estimated using data
from a Swedish population-based study. The penetrance function for non-carriers is based on
rates from the Thames Cancer Registry.
IBIS calculates a weighted average of the cumulative penetrances for each genotype:
P(T˜ ≤ t, J = B|H) =∑
γ,θ
P(T˜ ≤ t, J = B|Γ,Θ)P(Γ = γ,Θ = θ|H), (9)
where Θ denotes the proband’s carrier status with respect to the hypothetical gene (Θ = 0 for
non-carriers and Θ = 1 for carriers). In IBIS, joint carriers of BRCA1 and BRCA2 are modelled as
BRCA1 carriers.
The risk of developing breast cancer between ages a and a+ τ, conditional on not having breast
cancer at age a (we use a instead of a˜ here because while IBIS is based on the continuous-time
framework, integer-valued ages are used in the implementation), is
P(T˜ ≤ a + τ, J = B|T˜ > a, H, Y) =
∫ a+τ
a
λ˜B,H(t)s(Y) exp
{
−
∫ t
a
(λ˜B,H(u)s(Y) + λ˜D(u))du
}
dt,
(10)
where λ˜B,H(t) = lim
dt→0
P(t ≤ T˜ < t + dt, J = B|T˜ ≥ t, H)/dt and s(Y) is a normalized version of
the relative hazard of breast cancer associated with risk factors Y where the normalization factor
is the average relative hazard in the general population:
s(Y) = φ(Y)(1− AR) = φ(y)∫
φ(Y) f (Y)dy
(11)
where AR denotes the population attributable risk due to Y, φ(Y) is the relative hazard associated
with Y (relative to the no-risk population), and f (Y) is the prevalence of Y in the population. s(Y)
is approximated by
s(Y) ≈∏
j=1
φ(Yj)∫
φ(Yj) f (Yj)dy
(12)
using the assumption that the risk factors are independent (j indexes the risk factors in Y).
Software for running IBIS is available at http://www.ems-trials.org/riskevaluator/. We
used the command line program for version 8 and the competing mortality option.
2.3 Model Combination Approaches
2.3.1 Penetrance Modification Model: BRCAPRO+BCRAT (M)
Liu et al. [23] proposed to combine BRCAPRO and BCRAT by incorporating the relative hazards
for BCRAT covariates into the genotype-specific hazard functions in BRCAPRO. Since BCRAT is not
recommended for known carriers of pathogenic BRCA1/2 mutations (one of the patient eligibility
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criteria for using the risk calculator at https://bcrisktool.cancer.gov/calculator.html is the
absence of a positive BRCA1/2 test result), we propose to apply the relative hazards for the
BCRAT covariates to only the non-carrier hazard function in BRCAPRO.
We extend the BCRAT relative hazard model,
λ˜B(t|X) = λ˜B,0(t)r(t, X), (13)
where λ˜B(t|X) = lim
dt→0
P(t ≤ T˜ < t + dt, J = B|T˜ ≥ t, X)/dt, to obtain a model for non-carriers:
λ˜B(t|X, Γ = 0) = λ˜0B(t)r0(t, X), (14)
where λ˜B(t|X, Γ = 0) = lim
dt→0
P(t ≤ T˜ < t + dt, J = B|T˜ ≥ t, X, Γ = 0)/dt, λ˜0B(t) = limdt→0 P(t ≤ T˜ <
t + dt, J = B|T˜ ≥ t, Γ = 0)/dt, and r0(t, X) is the relative hazard of breast cancer compared to
the average hazard among non-carriers (discussed in more detail below). Models 13 and 14 are
continuous-time models. To incorporate the hazard modification into the discrete-time framework
used by BRCAPRO, we consider the discrete-time analogue induced by Equation 14 under the
setting where we observe only integer-valued t (see Chapter 2.4.2 of [46]):
λB(t|X, Γ = 0) = 1−
(
1− λ0B(t)
)r0(t,X)
, (15)
where λB(t|X, Γ = 0) = P(T = t, J = B|T ≥ t, X, Γ = 0).
We then modify the calculation of the non-carrier risk in BRCAPRO by replacing λ0B(t) in
Equation 2 with λB(t|X, Γ = 0) to get
P(T ≤ a+ τ, J = B|T > a, Γ = 0, X) =
a+τ
∑
t=a+1
(
1− (1− λ0B(t))r0(t,X)) t−1∏
u=a+1
((
1− λ0B(u)
)r0(u,X) − λD(u)) .
(16)
As in BRCAPRO, the final risk is a weighted average of the genotype-specific risks:
P(T ≤ a + τ, J = B|T > a, H, X) =
3
∑
γ=0
P(T ≤ a + τ, J = B|T > a, Γ = γ, X)P(Γ = γ|H). (17)
We refer to this model as the penetrance modification model, BRCAPRO+BCRAT (M), since
the modification of the hazard function induces a modification of the corresponding penetrance
function (see Equation 3). This combination approach is similar to replacing the non-carrier
future risk from BRCAPRO with the future risk from BCRAT, but adjusts for the slightly different
baseline hazards used in BRCAPRO and BCRAT (see Figure 5 in Appendix A for plots of the
estimated general population hazard for White women in BCRAT and the estimated non-carrier
hazard in BRCAPRO).
The relative hazard approach for incorporating the BCRAT risk factors has similarities to the
one used in IBIS, but IBIS averages the genotype-specific risks before incorporating non-genetic
risk factors, while BRCAPRO+BCRAT (M) incorporates the BCRAT risk factors before averaging
the genotype-specific risks. The advantage of the latter is that it allows for the effects of the
BCRAT risk factors to differ by genotype. Differing effects by genotype have been observed for
some BCRAT risk factors, such as age at menarche (see [47] for a review). However, in general,
the effects of the BCRAT risk factors on carriers are not well-studied (only a limited number of
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prospective studies have been done and they had small sample sizes [47]), so the current version
of BRCAPRO+BCRAT (M) modifies only the non-carrier hazards.
Similar to s(Y) from IBIS (Equation 11), r0(t, X) is a normalized version of r(t, X) where the
normalization factor is the average relative hazard among non-carriers:
r0(t, X) = r(t, X)(1− AR0(t)) = r(t, X)
∑X r(t, X)P(X|t, Γ = 0)dy
(18)
where AR0(t) is the population attributable risk fraction among non-carriers. The normalization
is necessary because r(t, X) modifies λ˜B,0(t) and is with respect to the no-risk population; in order
to modify λ0B(t), we need the relative hazard with respect to the non-carrier population.
Due to low mutation prevalence (the prevalence of BRCA1/2 mutations in the general pop-
ulation has been estimated at 1/400 [48]), we approximate AR0(t) with AR(t), i.e. we assume
P(X|t, Γ = 0) ≈ P(X|t). Therefore, BRCAPRO+BCRAT (M) takes parameters from existing models
and does not need to be trained on new data (however, the parameters should be updated as
new data becomes available). Though race-specific estimates of AR(t) are available from BCRAT,
they are based on data from the 1980s to early 2000s, so we re-estimated AR(t) based on the
distribution of BCRAT covariates in more recent data from the 2015 National Health Interview
Survey (NHIS), which uses a cross-sectional sample of U.S. adults designed to be representative
of the U.S. general population. As in IBIS (Equation 12), we assumed that the risk factors are
independent, except we used the joint distribution of age at first live birth and number of affected
first-degree relatives because Equation 5 includes an interaction between these variables. The
race-specific estimates from the NHIS are given in Appendix A.
Since P(Γ = γ|H) already accounts for family history, it may seem redundant to include
the BCRAT family history variable (X4, the number of affected first-degree relatives) among the
penetrance-modifying risk factors. However, its inclusion could be useful because 1) there is a
strong interaction between the family history variable and age at first live birth in BCRAT, and
2) the BCRAT family history variable could potentially account for residual familial risk due to
non-BRCA-related factors, such as low-penetrance genes and shared environmental factors, which
are not currently considered by BRCAPRO.
2.3.2 Ensemble Model: BRCAPRO+BCRAT (E)
The second model combination approach involves training a stacked ensemble model [24] that
uses BRCAPRO and BCRAT as the (pre-trained) base models. We consider a logistic regression
ensemble that predicts τ-year risk of breast cancer for fixed τ, as well as a time-to-event extension.
These models are both special cases of the direct binomial regression model proposed by Scheike
et al. (2008) [49] for time-to-event data with competing risks.
Let FB(τ) = P(T˜ ≤ a˜ + τ, J = B|T˜ > a˜, H, X). Let F1B(τ) be the τ-year BRCAPRO risk
prediction and F2B(τ) the τ-year BCRAT risk prediction. If interest lies in risk prediction for a fixed
value of τ, then as in Debray et al. (2014) [38], we can combine the τ-year BRCAPRO and BCRAT
predictions using the logistic regression model
log
FB(τ)
1− FB(τ) = β0 + β1F
1
B(τ) + β2F
2
B(τ) + β3F
1
B(τ)F
2
B(τ). (19)
Other covariates and/or published models can also be included as inputs. We refer to Model 19
as BRCAPRO+BCRAT (E).
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To predict risk for different values of τ, we extend Model 19 to include interactions with τ,
since the optimal coefficients for combining BRCAPRO and BCRAT may vary with τ:
log
FB(τ)
1− FB(τ) = β0+ β1F
1
B(τ)+ β2F
2
B(τ)+ β3F
1
B(τ)F
2
B(τ)+ β4τ+ β5τF
1
B(τ)+ β6τF
2
B(τ)+ β7τF
1
B(τ)F
2
B(τ).
(20)
We refer to Model 20 as BRCAPRO + BCRAT (E2).
Models 19 and 20 can be fit to competing risks data using generalized estimating equations
with inverse probability of censoring weights (IPCW) to account for right censoring [49, 50]. For
Model 20, we need to pre-specify a sequence of values of τ for applying logistic regression and use
a transformed version of the training dataset where each proband contributes one observation per
time point in the sequence [50]. One choice is to use all time points at which events were observed
in the training dataset [50]. For a given τ in the pre-specified sequence, a proband’s τ-year event
status may be unknown due to censoring. Let C˜ be the censoring time, G(t|H, X) = P(C˜ > t|H, X),
∆ = I[T˜ ≤ C˜], and NB(t) = I[T˜ ≤ t, J = B]. We assume (T˜, J) are independent of C given (H, X).
To account for unobserved τ-year events using IPCW, we replace the outcomes NB(τ) of those
who developed cancer within τ years by ∆NB(τ)/G(T˜|H, X) [49] when we fit the regression
model. The weighting is justified by the relationship
E
[
∆NB(τ)
G(T˜|H, X)
]
= E
[
E
[
∆NB(τ)
G(T˜|H, X)
∣∣∣ T, J, H, X]] = E[NB(τ)|H, X] = FB(τ).
The censoring distribution G can be estimated using the Kaplan-Meier method if censoring is
assumed to be independent of the covariates. Otherwise, a stratified Kaplan-Meier estimator or a
semiparametric regression model such as the Cox proportional hazards model could be used.
This combination approach assumes that predictions from BRCAPRO and BCRAT are not
highly correlated (otherwise, multicollinearity may lead to unstable coefficient estimates [51]).
In contrast to the penetrance modification model, the ensemble models need to be trained
using prospective follow-up data. The ensemble model should ideally be trained on a dataset
representative of the target population. When the training data are not representative of the
target population, reweighting methods can be used to account for differences in the covariate
distributions. One widely used method is importance weighting [52], which weights each training
observation by the ratio of the joint probability distributions of the covariates in the target and
training populations [52]. The importance weights can be estimated using kernel mean matching
[53], Kullback-Leibler importance estimation [54], or least squares importance fitting [55].
In the simulations and data application, we square root-transformed the BRCAPRO and
BCRAT predictions prior to fitting/applying the ensemble models since the distributions of
the predictions were highly right-skewed. We fit BRCAPRO+ BCRAT (E2) using the geepack R
package (https://cran.r-project.org/web/packages/geepack/index.html), version 1.3-1, with
a working autoregressive (AR-1) correlation structure. We used information from yearly time
points τ = 1, . . . , τ∗, where τ∗ denotes the latest event time (in years from baseline) observed in
the training dataset.
2.4 Model Evaluation Metrics
In the simulations and data application, we considered the binary outcome of being diagnosed
with breast cancer within τ = 5 years. In the data application, we also considered the time-to-event
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outcome over the course of follow-up because many of the probands in the validation dataset
were followed for more than 5 years, but there was a fair amount of variability in follow-up times.
We used five performance measures [56]: 1) the ratio of observed (O) to expected (E) events
(where E is calculated by summing everyone’s predicted probabilities), a measure of calibration
(with 1 indicating perfect calibration); 2) the area under the receiver operating characteristic curve
(AUC) or concordance (C) statistic, which is the probability that an individual who experiences
the event has a higher score than an individual who does not and is a measure of discrimination;
3) the Brier score, which is the mean squared difference between the predicted probabilities
and actual outcomes; 4) standardized net benefit (SNB) [57], which is the difference between
the true positive rate and a weighted false positive rate, based on a pre-specified risk threshold
(the weight is the ratio of the odds of the threshold risk to the odds of the outcome); and 5) the
logarithmic score [58], which is the negative log-likelihood. Calibration was assessed using both
overall O/E and calibration plots of O/E by risk decile. We only calculated SNB for the binary
outcome, using a 5-year risk threshold of 1.67% (the clinical 5-year risk threshold for eligibility for
chemoprevention). We report the Brier score and logarithmic score in terms of relative difference
with respect to BRCAPRO since these metrics are prevalence-dependent and therefore more
difficult to interpret on their original scale.
Since there was censoring in the validation data for the data application (some individuals were
followed for fewer than τ = 5 years and were breast-cancer free when they were lost to follow-up),
we used IPCW [59, 60] to calculate the O/E, AUC, Brier score, and logarithmic score for the
binary outcome: individuals with observed outcomes were used to calculate the performance
measures and weighted by their inverse probability of not being censored by the minimum of
1) their age at the end of the projection period, and 2) the age at which they were diagnosed
with breast cancer. An individual was weighted by 1/G(a + τ) if they did not develop cancer
within τ years and 1/G(TB) otherwise. Individuals who were censored were not directly used to
calculate the performance measures, but were used to estimate the censoring distribution, G, via
the Kaplan-Meier method.
For the time-to-event outcome, O/E was calculated by comparing the observed to expected
cases across the entire study period (for E, we predicted risk up to the end of indivudal follow-up
time for each proband, so τ varied across probands). We also used time-to-event versions of the
C-statistic [61] and logarithmic score [62]. The time-to-event C-statistic [61] is the probability that
an individual with a shorter time to event has a higher score than an individual with a longer
time to event. We used a constant τ = 10 to calculate the C-statistic (which requires the same
prediction period for everyone) since 10 years was the maximum event time observed in the data.
We calculated 95% bootstrap confidence intervals (CIs) for all of the performance measures
except for the time-to-event C-statistic, whose 95% CI was obtained using perturbation resampling
[61].
3 Simulations
We compared the 5-year performance of the combination models to the individual BRCAPRO and
BCRAT models in data simulated under the assumptions of the penetrance modification model.
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3.1 Data Generation
We first generated each proband’s baseline family history, consisting of 1) the family structure, 2)
dates of birth, 3) genotypes, and 4) cancer ages and death ages.
We simulated pedigrees to mimic family structures observed in real families from the CGN
dataset (the validation dataset for the data application, described in Section 4.1), including the
number of sisters, number of brothers, and so on. We restricted the family members to first- and
second-degree relatives of the proband.
For probands, dates of birth and baseline dates for risk assessment were also sampled from the
CGN dataset. For non-probands, dates of birth were generated relative to the proband’s date of
birth by assuming that the age difference between a parent and a child has mean 27 and standard
deviation 6. We generated the birth dates of the proband’s parents and children based on the
proband’s birth date, then the birth dates of the proband’s grandparents and siblings based on the
birth dates of the parents, then the birth dates of the proband’s aunts and uncles based on the
birth dates of the grandmothers.
Next, we generated the BRCA genotypes for each family member. We first generated the
genotypes of the grandparents using the default Ashkenazi Jewish allele frequencies for BRCA1
and BRCA2 in BRCAPRO to mimic a higher-risk population (CGN participants represent a
higher-risk population than the general population since they were selected for family history
of cancer). For individuals in subsequent generations, we generated genotypes according to
Mendelian inheritance.
For all individuals, we generated baseline breast and ovarian cancer phenotypes conditional on
genotype. Ages of onset were sampled from {1, 2, . . . , current age}, with probabilities given by the
genotype-specific penetrance functions from BRCAPRO, and the probability of being unaffected
at baseline given by one minus the cumulative penetrance up to the current age. Probands were
assumed to be alive at baseline, but we generated a death age for each non-proband from a
distribution with mean 80 and standard deviation of 15. If an individual had cancer with an
age of onset greater than their age at death, then the individual’s cancer status was changed to
unaffected. Probands with breast cancer at baseline were excluded from the analyses.
We then generated baseline BCRAT covariates (excluding number of affected first-degree
relatives and age at first live birth, which were calculated from the baseline family history), by
sampling values from the distribution in the CGN. Values for different covariates were sampled
independently of each other. The BCRAT covariates were used to modify the BRCAPRO non-
carrier penetrance to obtain the BRCAPRO+BCRAT (M) non-carrier penetrance (Equation 16).
For probands who did not have breast cancer at baseline, future ages of onset were generated
from the BRCAPRO+BCRAT (M) penetrances (for carriers, the BRCAPRO+BCRAT (M) penetrances
are the same as in BRCAPRO), which were rescaled to be conditional on not having developed
cancer by the baseline age. Cases were defined as probands who developed breast cancer within 5
years of their baseline age. The 5-year outcomes were not subject to censoring.
After excluding 4,443 probands who had breast cancer at baseline, we used 50,000 probands
to train the ensemble model (similar to the size of the training set in the data application - see
Section 4.1) and the remaining 45,557 for validation. There were 814 cases in the training set and
724 cases in the validation set.
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3.2 Results
The performance measures are given in Table 1 and calibration plots are given in Figure 2.
BRCAPRO+BRCAT (M), the true model, had the best performance, but the ensemble models were
able to achieve similar performance to the true model and performance gains over BRCAPRO and
BCRAT. The combination models were well-calibrated overall, with O/E=1.01 (95% CI 0.94-1.08) for
BRCAPRO+BCRAT (M), O/E=0.98 (95% CI 0.91-1.04) for BRCAPRO+BCRAT (E), and O/E=1.00
(95% CI 0.93-1.07) for BRCAPRO+BCRAT (E2), while BRCAPRO and BCRAT underpredicted
the number of cases, with O/E=1.14 (95% CI 1.07-1.22) for BRCAPRO and O/E=1.13 (95% CI
1.05-1.20) for BCRAT. The combination models were well-calibrated in each decile of risk (Figure
2), while BRCAPRO and BCRAT were more prone to underpredicting risk in certain deciles.
The combination models had slightly higher AUCs than BRCAPRO and BCRAT: 0.69 (95% CI
0.67-0.71 for BRCAPRO+BCRAT (M), 0.68 (95% CI 0.67-0.70) for BRCAPRO+BCRAT (E) and
BRCAPRO+BCRAT (E2), 0.67 (95% CI 0.65-0.69) for BRCAPRO, and 0.66 (95% CI 0.64-0.68) for
BRCAT. Also, the combination models performed better than BRCAPRO and BCRAT with respect
to the Brier score, logarithmic score, and SNB. Across 1000 bootstrap replicates of the validation
dataset, all of the combination models outperformed BRCAPRO and BCRAT with respect to all
performance measures in more than 95% of the replicates. BRCAPRO+BCRAT (M) outperformed
BRCAPRO+BCRAT (E) and BRCAPRO+BCRAT (E2) more than 99% of the time with respect to
AUC, Brier score, and logarithmic score.
O/E AUC SNB ∆BS ∆LS
Performance Metrics
B+B (M) 1.01 (0.94, 1.08) 0.69 (0.67, 0.71) 0.26 (0.21, 0.30) 0.25 (0.09, 0.41) 1.12 (0.60, 1.66)
B+B (E) 0.98 (0.91, 1.04) 0.68 (0.67, 0.70) 0.25 (0.20, 0.29) 0.12 (-0.02, 0.25) 0.63 (0.18, 1.05)
B+B (E2) 1.00 (0.93, 1.07) 0.68 (0.67, 0.70) 0.24 (0.19, 0.28) 0.13 (-0.03, 0.27) 0.61 (0.17, 1.06)
BRCAPRO 1.15 (1.07, 1.23) 0.67 (0.65, 0.69) 0.21 (0.17, 0.25) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.14 (1.05, 1.21) 0.66 (0.64, 0.68) 0.20 (0.15, 0.24) -0.21 (-0.46, 0.06) -1.15 (-2.10, -0.16)
B+B(M)>B+B(E) 0.570 0.994 0.725 0.999 1.000
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E2) 0.422 0.994 0.886 0.995 1.000
B+B(M)>BRCAPRO 0.978 0.999 0.998 0.998 1.000
B+B(M)>BCRAT 0.962 1.000 1.000 1.000 1.000
B+B(E)>B+B(E2) 0.401 0.625 0.920 0.235 0.653
B+B(E)>BRCAPRO 0.944 0.999 1.000 0.961 0.998
B+B(E)>BCRAT 0.924 1.000 0.999 0.994 1.000
B+B(E2)>BRCAPRO 0.974 0.999 0.991 0.957 0.996
B+B(E2)>BCRAT 0.952 1.000 0.998 0.995 1.000
Table 1: 5-year performance in a simulated dataset with 45,557 probands (717 cases). B+B:
BRCAPRO+BCRAT. ∆BS: % relative improvement in Brier Score compared to BRCAPRO. ∆LS: %
relative improvement in logarithmic score compared to BRCAPRO. The “Comparisons Across
Bootstrap Replicates" section shows pairwise comparisons involving the combination models
across 1000 bootstrap replicates of the validation dataset; the row for A > B shows the proportion
of bootstrap replicates where model A outperformed model B with respect to each metric.
Proportions > 0.5 are highlighted in blue (with darker shades of blue for higher proportions) and
proportions ≤ 0.5 are highlighted in red (with darker shades of red for lower proportions).
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Figure 2: Calibration plots by decile of risk for 5-year predictions in a simulated dataset with
45,557 probands (724 cases).
4 Data Application
We trained ensemble models 19 for τ = 5 and 20 for time-to-event outcome using data from
the Newton-Wellesley Hospital (NWH) and validated them, along with BRCAPRO+BCRAT (M),
BRCAPRO, BCRAT, and IBIS, on data from the CGN. We assessed performance based on both the
binary outcome of breast cancer diagnosis within τ = 5 years and the time-to-event outcome. We
also looked at performance stratified by family history, with strata defined based on the NCCN
criteria for further genetic risk evaluation [63].
In the analyses, we excluded women with invasive breast cancer/ductal carcinoma in situ/lobular
carcinoma in situ/bilateral mastectomy/bilateral oophorectomy prior to baseline, women who
tested positive for BRCA1/2 prior to baseline (BCRAT requirement), women < 20 years old at
baseline (BCRAT requirement), and women with projection age > 85 years old (IBIS requirement).
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4.1 Datasets
The characteristics of the training and validation datasets are summarized in Table 2.
4.1.1 NWH
After applying the exclusion criteria, the training cohort consisted of 37,881 women who vis-
ited the breast imaging department of the NWH in Newton, Massachusetts for screening or
diagnostic imaging from February 2007 through December 2009. During the initial (baseline)
visit, information was collected on personal and family history of cancer, reproductive history,
sociodemographic factors, and lifestyle factors. Family history was limited to relatives with
cancer. Breast cancer diagnoses through 2015 were determined from the Massachusetts State
Cancer Registry, Partners Hospital Cancer Registries, and patient self-reporting. The median
age of the probands was 49, with an inter-quartile range (IQR) of 43-58. 30,758 (81.2%) of the
probands were White. 5,684 (15.0%) had at least one affected first- or second-degree relative.
The median follow-up time was 6.7 years (IQR 6.3-7.2). All probands were followed for at least
6 years, so we did not need to use IPCW to fit BRCAPRO+BCRAT (E) for τ = 5 years. To fit
BRCAPRO+BCRAT (E2), we used the Kaplan-Meier method to estimate the censoring distribution
for IPCW. There were 495 probands (1.3%) who developed breast cancer within 5 years of baseline
and 714 probands (1.9%) who developed breast cancer over the course of follow-up.
Since the NWH cohort represents a general screening population while the CGN validation
cohort (described below) represents a higher-risk population enriched for family history of cancer,
we applied importance weights to the training data based on the distributions of the BCRAT
covariates, 5-year BCRAT predictions, and 5-year BRCAPRO predictions when we fit the ensemble
models. The weights were estimated using least squares importance fitting via the densratio R
package https://cran.r-project.org/web/packages/densratio/index.html.
4.1.2 CGN
The validation cohort consists of 7,314 women who enrolled in the CGN, a national research
network consisting of 15 academic medical centers that was established for the purpose of studying
inherited predisposition to cancer. Enrollment began in 1999 and ended in 2010. One of the criteria
for enrollment was a personal and/or family history of cancer. Participants provided information
on personal and family history of cancer, sociodemographic factors and lifestyle factors through an
initial (baseline) phone interview and annual follow-up updates. From 2009 onward, information
was also collected on reproductive history, cancer treatments, cancer screening results, and genetic
testing results.
The median age of the probands was 47 (IQR 38-57); 6,104 (83.5%) of the probands were White.
3,143 (42.9%) had at least one female first-degree relative with breast cancer. The median follow-
up time was 7.3 years (IQR 6.0-8.3) and 934 (12.8%) probands were censored within 5 years of
baseline without being diagnosed with breast cancer. 159 (2.2%) probands developed breast cancer
during follow-up, with 112 of the diagnoses occurring within 5 years of baseline. Demographic
characteristics stratified by center are given in Table 8 in Appendix C. Since follow-up times and
breast cancer incidence rates varied by center, we estimated the censoring distribution by fitting a
Kaplan-Meier curve for each center separately.
Information on some risk factors was missing or incomplete. We did not have information
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on atypical hyperplasia (used in BCRAT and IBIS), breast density (used in IBIS), polygenic risk
scores (used in IBIS, or hormone replacement therapy (used in IBIS). Participants were asked
whether they had ever had a benign breast biopsy but were not asked about the number of
biopsies (categorized as 0, 1, or ≥ 2 in BCRAT). Since participants were asked about reproductive
history starting in 2009, 4,157 (56.8%) were missing age at menarche (used in BCRAT and IBIS).
Ashkenazi Jewish status (used in BRCAPRO and IBIS) was not available for the UWASH center.
We coded the missing variables according to the specifications of the software for each model.
Number of breast biopsies was coded as 1 for participants who indicated that they had previously
had a biopsy.
Variable Category CGN NWH
N 7314 37881
Age (median [IQR]) 47 [38, 57] 49 [43, 58]
Race (%) White 6104 (83.5) 30758 (81.2)
Black 257 (3.5) 479 (1.3)
Hispanic 694 (9.5) 548 (1.4)
Asian 160 (2.2) 1228 (3.2)
Native American 29 (0.4) 25 (0.1)
Unknown 70 (1.0) 4843 (12.8)
Affected 1st-degree Relatives (%) 0 4171 (57.0) 32197 (85.0)
1 2496 (34.1) 5277 (13.9)
2+ 647 (8.8) 407 (1.1)
Follow-up Time (median [IQR]) 7.3 [6.0, 8.3] 6.7 [6.3, 7.2]
Censored <5 Years (%) 934 (12.8) 0 (0.0)
Cases (%) 159 (2.2) 714 (1.9)
5-year Cases (%) 112 (1.5) 495 (1.3)
Table 2: Cohort characteristics.
4.2 Results
4.2.1 5-year Binary Outcome
The performance measures based on the 5-year outcome are shown in Tables 3 (overall perfor-
mance) and 4 (performance stratified by family history). Calibration plots are shown in Figure
3 and scatter plots, density plots, and correlations are shown in Figure 4. The weights from the
ensemble models are provided in Appendix B.
Predictions from BRCAPRO+BCRAT (M) were highly correlated with predictions from each
of the other models in the entire cohort (Figure 4), with Pearson correlation coefficients ranging
from ρ = 0.78 with BRCAPRO to ρ = 0.93 with BRCAPRO+BCRAT (E). BRCAPRO+BCRAT
(E), which assigned a higher weight to BCRAT than to BRCAPRO (see Appendix B), was very
highly correlated with BCRAT (ρ = 0.93) and moderately correlated with BRCAPRO (ρ = 0.67),
while BRCAPRO+BCRAT (E2) assigned similar weights to BRCAPRO and BCRAT and was highly
correlated with both models (ρ = 0.80 and ρ = 0.75).
BRCAPRO+BCRAT (M) (O/E=1.03, 95% CI 0.85-1.23) and IBIS (O/E=0.98, 95% CI 0.81-
1.17) well-calibrated overall while BCRAT (O/E=1.15, 95% CI 0.95-1.37), BRCAPRO+BCRAT (E)
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(O/E=1.17, 95% CI 0.97-1.40), BRCAPRO+BCRAT (E2) (O/E=1.22, 95% CI 1.00-1.45), and BR-
CAPRO (O/E=1.30, 95% CI 1.07-1.55) underestimated risk. BRCAPRO+BCRAT (M) overestimated
risk in the top decile of risk and IBIS overestimated risk in the second highest decile, while
BRCAPRO and BCRAT underestimated risk in several deciles (Figure 3). The AUCs were 0.68
(95% CI 0.63-0.72) for the combination models, 0.67 for IBIS (95% CI 0.62-0.71), 0.66 for BCRAT
(95% CI 0.62-0.71), and 0.65 (95% CI 0.61-0.70) for BRCAPRO. IBIS had the highest SNB (SNB=0.28,
95% CI 0.16-0.39), followed by BRCAPRO+BCRAT (M) (SNB=0.24, 95% CI 0.13-0.35) and the
ensemble models (SNB=0.23, 95% CI 0.11-0.33 for (E) and 0.11-0.34 for (E2)). All models performed
similarly with respect to the Brier score and logarithmic score. Across 1000 bootstrap replicates,
BRCAPRO+BCRAT (M) outperformed BRCAPRO and BCRAT with respect to all performance
measures except the Brier score in the majority of the replicates. In particular, BRCAPRO+BCRAT
(M) had a higher SNB than BRCAPRO /BCRAT 95% of the time or more. Both ensemble models
outperformed BRCAPRO and BCRAT with respect to all metrics except O/E in the majority of
the replicates. Also, the combination models outperformed IBIS with respect to AUC, Brier score,
and logarithmic score in the majority of the replicates, but IBIS had better calibration and SNB in
most replicates.
In probands who met the NCCN criteria for further genetic risk evaluation (Table 4), the
combination models and IBIS had higher AUCs and SNBs than BRCAPRO and BCRAT. BR-
CAPRO+BCRAT (M) and IBIS overestimated risk while all other models except BCRAT underesti-
mated risk. In probands who did not meet the NCCN criteria, all models underestimated risk.
BRCAPRO had a slightly lower AUC than the other models and IBIS had the highest SNB.
4.2.2 Time-to-Event Outcome
The performance measures based on the time-to-event outcome are shown in Tables 9 (overall
performance) and 10 (performance stratified by family history) in Appendix C. BRCAPRO+BCRAT
(E) was excluded from the analyses because it only provides 5-year risks. We did not calculate
the logarithmic score for BRCAPRO+BCRAT (E2) and IBIS because BRCAPRO+BCRAT (E2) the
cause-specific distribution for competing mortality, which is needed to calculate the likelihood,
is not explicitly modelled by BRCAPRO+BCRAT (E2) and cannot be easily extracted from the
software for IBIS.
The relative performance of the models for the time-to-event outcome was similar to the
relative performance for the 5-year outcome. O/E and discriminatory accuracy did not change
substantially compared to Tables 3 and 10, and differences in Brier score and logarithmic score
across models were small. BRCAPRO+BCRAT (M) and BRCAPRO+BCRAT (E2) performed
similarly to BCRAT and IBIS overall (Table 9) and had higher C-statistics than BCRAT in the
subset of probands meeting the NCCN criteria (Table 10). The combination models also had better
calibration and discrimination than BRCAPRO overall and within each family history stratum.
5 Discussion and Conclusion
The availability and use of multiple risk prediction models can lead to confusion in clinical
practice. Combining models addresses this problem and also provides a way to develop more
comprehensive models without building new models from the ground up, which can save a
considerable amount of time and effort. We combined BRCAPRO, a Mendelian model based
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O/E AUC SNB ∆BS ∆LS
Performance Metrics
B+B (M) 1.03 (0.85, 1.23) 0.68 (0.63, 0.72) 0.24 (0.13, 0.35) 0.21 (-0.43, 0.84) 1.61 (-0.54, 3.64)
B+B (E) 1.17 (0.97, 1.40) 0.68 (0.63, 0.72) 0.23 (0.11, 0.33) 0.38 (-0.09, 0.90) 1.74 (-0.10, 3.52)
B+B (E2) 1.22 (1.00, 1.45) 0.68 (0.63, 0.72) 0.23 (0.11, 0.34) 0.32 (0.00, 0.66) 1.58 (0.17, 3.04)
BRCAPRO 1.30 (1.07, 1.55) 0.65 (0.61, 0.70) 0.17 (0.06, 0.27) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.15 (0.95, 1.37) 0.66 (0.62, 0.71) 0.18 (0.07, 0.29) 0.22 (-0.53, 0.97) 0.88 (-2.05, 3.47)
IBIS 0.98 (0.81, 1.17) 0.67 (0.62, 0.71) 0.28 (0.16, 0.39) -0.05 (-0.69, 0.51) 0.89 (-1.56, 2.95)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E) 0.839 0.418 0.680 0.203 0.399
B+B(M)>B+B(E2) 0.892 0.439 0.609 0.327 0.508
B+B(M)>BRCAPRO 0.950 0.931 0.950 0.757 0.932
B+B(M)>BCRAT 0.807 0.760 0.980 0.456 0.778
B+B(M)>IBIS 0.460 0.745 0.191 0.825 0.789
B+B(E)>B+B(E2) 0.969 0.578 0.408 0.703 0.708
B+B(E)>BRCAPRO 0.988 0.960 0.914 0.935 0.969
B+B(E)>BCRAT 0.055 0.849 0.867 0.871 0.906
B+B(E)>IBIS 0.223 0.749 0.150 0.909 0.813
B+B(E2)>BRCAPRO 0.995 0.979 0.940 0.976 0.986
B+B(E2)>BCRAT 0.038 0.785 0.870 0.659 0.756
B+B(E2)>IBIS 0.163 0.735 0.190 0.893 0.768
Table 3: 5-year performance in the entire CGN cohort. B+B: BRCAPRO+BCRAT. ∆BS: % relative
improvement in Brier Score compared to BRCAPRO. ∆LS: % relative improvement in logarithmic
score compared to BRCAPRO. The “Comparisons Across Bootstrap Replicates" section shows
pairwise comparisons involving the combination models across 1000 bootstrap replicates of the
validation dataset; the row for A > B shows the proportion of bootstrap replicates where model
A outperformed model B with respect to each metric. Proportions > 0.5 are highlighted in blue
(with darker shades of blue for higher proportions) and proportions ≤ 0.5 are highlighted in red
(with darker shades of red for lower proportions).
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O/E AUC SNB ∆BS ∆LS
Strong Family History (34 cases)
Performance Metrics
B+B (M) 0.81 (0.55, 1.09) 0.71 (0.63, 0.79) 0.44 (0.20, 0.59) 0.75 (-1.41, 2.29) 3.62 (-3.05, 7.97)
B+B (E) 1.07 (0.73, 1.44) 0.71 (0.62, 0.79) 0.41 (0.17, 0.57) 1.19 (-0.21, 2.48) 4.15 (-0.75, 8.42)
B+B (E2) 1.16 (0.78, 1.55) 0.71 (0.63, 0.79) 0.41 (0.17, 0.57) 1.03 (0.12, 1.88) 3.86 (0.03, 7.00)
BRCAPRO 1.32 (0.88, 1.79) 0.66 (0.58, 0.74) 0.30 (0.09, 0.47) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.03 (0.70, 1.38) 0.66 (0.57, 0.76) 0.31 (0.06, 0.47) 0.77 (-1.42, 2.70) 1.55 (-6.27, 8.10)
IBIS 0.74 (0.50, 0.99) 0.69 (0.61, 0.77) 0.41 (0.14, 0.57) -0.15 (-2.38, 1.33) 1.12 (-5.97, 5.56)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E) 0.344 0.607 0.645 0.183 0.321
B+B(M)>B+B(E2) 0.445 0.513 0.679 0.325 0.434
B+B(M)>BRCAPRO 0.609 0.939 0.905 0.792 0.885
B+B(M)>BCRAT 0.284 0.908 0.952 0.462 0.766
B+B(M)>IBIS 0.954 0.692 0.707 0.869 0.909
B+B(E)>B+B(E2) 0.707 0.436 0.790 0.666 0.616
B+B(E)>BRCAPRO 0.824 0.851 0.896 0.949 0.952
B+B(E)>BCRAT 0.416 0.953 0.866 0.837 0.941
B+B(E)>IBIS 0.747 0.639 0.537 0.916 0.889
B+B(E2)>BRCAPRO 0.874 0.902 0.890 0.987 0.976
B+B(E2)>BCRAT 0.334 0.885 0.863 0.634 0.801
B+B(E2)>IBIS 0.641 0.669 0.515 0.893 0.871
Less Family History (78 cases)
Performance Metrics
B+B (M) 1.16 (0.91, 1.42) 0.65 (0.60, 0.71) 0.16 (0.02, 0.28) -0.02 (-0.48, 0.37) 0.80 (-1.15, 2.55)
B+B (E) 1.21 (0.95, 1.49) 0.66 (0.60, 0.71) 0.14 (-0.01, 0.27) 0.03 (-0.22, 0.26) 0.80 (-0.64, 2.18)
B+B (E2) 1.24 (0.97, 1.51) 0.66 (0.60, 0.71) 0.15 (-0.01, 0.28) 0.02 (-0.18, 0.21) 0.70 (-0.48, 1.90)
BRCAPRO 1.28 (1.00, 1.57) 0.63 (0.58, 0.68) 0.10 (-0.04, 0.22) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.20 (0.94, 1.47) 0.66 (0.60, 0.72) 0.12 (-0.02, 0.25) -0.01 (-0.43, 0.36) 0.68 (-1.68, 3.02)
IBIS 1.14 (0.89, 1.39) 0.66 (0.60, 0.71) 0.22 (0.07, 0.35) -0.01 (-0.43, 0.38) 0.81 (-1.40, 2.95)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E) 0.918 0.294 0.646 0.336 0.487
B+B(M)>B+B(E2) 0.927 0.428 0.555 0.361 0.550
B+B(M)>BRCAPRO 0.949 0.860 0.815 0.446 0.789
B+B(M)>BCRAT 0.912 0.248 0.898 0.429 0.557
B+B(M)>IBIS 0.132 0.412 0.122 0.434 0.483
B+B(E)>B+B(E2) 0.948 0.814 0.389 0.539 0.710
B+B(E)>BRCAPRO 0.960 0.945 0.791 0.607 0.867
B+B(E)>BCRAT 0.078 0.383 0.678 0.714 0.579
B+B(E)>IBIS 0.094 0.510 0.113 0.588 0.494
B+B(E2)>BRCAPRO 0.965 0.956 0.850 0.582 0.879
B+B(E2)>BCRAT 0.058 0.322 0.710 0.613 0.497
B+B(E2)>IBIS 0.080 0.459 0.155 0.570 0.447
Table 4: 5-year performance in the CGN cohort, stratified by family history (whether or not
the proband met the NCCN criteria for further genetic risk evaluation [63]; in applying the
criteria, we only used information on breast and ovarian cancer diagnoses in relatives). B+B:
BRCAPRO+BCRAT. ∆BS: % relative improvement in Brier Score compared to BRCAPRO. The
“Comparisons Across Bootstrap Replicates" section shows pairwise comparisons involving the
combination models across 1000 bootstrap replicates of the validation dataset; the row for A > B
shows the proportion of bootstrap replicates where model A outperformed model B with respect
to each metric. Proportions > 0.5 are highlighted in blue (with darker shades of blue for higher
proportions) and proportions ≤ 0.5 are highlighted in red (with darker shades of red for lower
proportions).
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Figure 3: Calibration plots.
on detailed family history information, and BCRAT, an empirical model based on a simple
summary of family history and various non-genetic risk factors, using two approaches, penetrance
modification and ensemble learning. The penetrance modification model, BRCAPRO+BCRAT (M),
and the ensemble models, BRCAPRO+BCRAT (E) for binary outcomes and BRCAPRO+BCRAT
(E2) for time-to-event outcomes, all achieved accuracy improvements over BRCAPRO and BCRAT
in simulations and data from the CGN, showing the value of augmenting the family history input
to BRCAPRO with non-genetic risk factors and augmenting the BCRAT risk factors with more
detailed family history information.
In data simulated under the penetrance modification model, the combination models out-
performed BRCAPRO and BCRAT with respect to calibration, discrimination, net benefit, and
prediction accuracy based on the Brier score and logarithmic score. In the CGN cohort, where
we also validated IBIS, an existing model that combines detailed family history with non-genetic
risk factors, the penetrance modification model achieved comparable performance to IBIS, out-
performing BRCAPRO overall and achieving better discrimination and net benefit than BCRAT
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Figure 4: Scatter plots, density plots, and correlations stratified by outcome. Red corresponds to
cases, blue corresponds to non-cases, and grey corresponds to probands censored before 5 years.
among women with a strong family history of breast/ovarian cancer. The ensemble models also
outperformed BRCAPRO overall and outperformed BCRAT among women with a strong family
history, but had worse overall calibration than the penetrance modification model. While BCRAT
performed well in the entire CGN cohort, the fact that it had less discrimination and net benefit
than IBIS and the combination models in probands meeting the NCCN criteria highlights the
importance of collecting detailed family history information for higher-risk subgroups where
early screening and prevention measures can substantially reduce cancer risk and mortality [64].
Furthermore, BCRAT is not suitable for known BRCA1/2 carriers, while the other four models
all take into account genetic testing results (the ensemble models do so indirectly through the
BRCAPRO risk prediction).
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Missing information on BRCAT and IBIS risk factors in the CGN dataset (atypical hyperplasia,
age at menarche, and, for IBIS, breast density, hormone replacement therapy, and polygenic risk
scores) could potentially have affected the discrimination of BCRAT, IBIS, and the combination
models, but they still had relatively good discrimination. The CGN also did not collect genetic
testing information for non-probands, which could considerably improve the discrimination of
BRCAPRO, IBIS, and the combination models [65]. Further validation in independent prospective
studies is needed, especially larger studies with more complete covariate information.
One limitation of applying the ensemble models trained on NWH data to the CGN cohort is
that the training cohort was not representative of the validation cohort. The NWH cohort was a
lower-risk cohort (as seen in Table 4.1, it had a lower proportion of women with a first-degree
family history of breast cancer) and the family history information available for the NWH cohort
was less detailed than that for the CGN cohort. We used importance weighting to address this
limitation, but since this approach relies on accurate estimation of the probability distributions of
risk factors in the training and target populations, the ensemble models we trained may have been
sub-optimal for CGN participants. The performance of the ensemble approach could potentially be
improved by training on data that is more representative of the validation data. This is supported
by fact that the ensemble models were well-calibrated in the simulations, where the training and
validation datasets were both generated under BRCAPRO+BCRAT (M).
The two combination approaches each have their strengths and limitations. Ensembling
via logistic regression calibrates the model to the training data, which can be a strength or a
limitation depending on how well the training data represents the target population. The model
might require recalibration in order to be suitable for a population different from the training
population. Differences between the training and validation populations could also negatively
affect discrimination and other performance measures. The penetrance modification model, on the
other hand, does not require training, but relies on accurate estimates of prevalence, penetrance,
and relative hazards. These estimates should be updated as new information becomes available.
Another disadvantage of ensembling via logistic regression is the need to estimate the censoring
distribution when there are probands in the training dataset who are censored before the last time
point of interest. One advantage of ensembling is its greater flexibility compared to the penetrance
modification approach. Ensembling can easily handle any number of models that can be of any
form. Including additional risk factors is also straightforward. The penetrance modification
model requires more assumptions because it specifically combines a model based on Mendelian
inheritance with a relative hazard model. Additional risk modifiers can be incorporated as new
relative hazard estimates become available, but it is important to properly scale the relative hazards
to be compatible with the hazard functions they are meant to modify and to consider whether the
effects of the risk modifiers differ by carrier status. BRCAPRO+BCRAT (M) currently modifies
only the non-carrier hazard function using the BCRAT relative hazard. Future work is needed
to extend the model to include modifiers of the carrier hazard functions. One more advantage
of ensembling is that once the model is trained, it only requires the predictions from the models
being combined and not the raw inputs (besides any additional risk factors that are explicitly
included in the ensemble model), which are potentially less accessible than the predictions.
Given our validation results, the penetrance modification approach seems more promising
than ensembling in the context of breast cancer risk prediction. BRCAPRO+BCRAT (M) achieved
competitive performance by leveraging the strengths of BRCAPRO and BCRAT, improving on
aspects of both models.
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Appendices
A Penetrance Modification Parameters
Hazard Functions in BRCAPRO and BCRAT
Figure 5: BCRAT cause-specific hazard of breast cancer for White women in the general population
(λ˜B(t) = λ˜B,0(t)/(1− AR(t))) and BRCAPRO cause-specific hazard of breast cancer for White
female non-carriers (λ0B(t)).
Population Attributable Risk Estimates for BCRAT Covariates
White Black Hispanic Asian Native American
< 50 1.81 1.41 1.37 2.10 1.55
≥ 50 1.96 1.44 1.41 2.43 1.94
Table 5: Estimates of (1− AR(t)) from NHIS 2015.
28
B Ensemble Weights From NWH
For BRCAPRO + BCRAT (E), we fit the model
log
FB(τ)
1− FB(τ) = β0 + β1
√
F1B(τ) + β2
√
F2B(τ) + β3
√
F1B(τ)
√
F2B(τ),
to the NWH cohort, where τ = 5. The estimated weights are given below.
Estimate Standard Error
βˆ0 2.55 1.31
βˆ1 0.86 0.32
βˆ2 1.21 0.28
βˆ3 0.11 0.06
Table 6: Coefficient estimates for BRCAPRO + BCRAT (E).
For BRCAPRO + BCRAT (E2), we fit the model
log
FB(τ)
1− FB(τ) = β0 + β1
√
F1B(τ) + β2
√
F2B(τ) + β3
√
F1B(τ)
√
F2B(τ) + β4τ + β5τ
√
F1B(τ) + β6τ
√
F2B(τ)+
β7τ
√
F1B(τ)
√
F2B(τ).
to the NWH cohort using observations from years τ = 1, . . . , 8. The estimated weights are given
below.
Estimate Standard Error
βˆ_0 -10.28 0.99
βˆ_1 43.11 11.53
βˆ_2 38.30 7.67
βˆ_3 0.35 0.13
βˆ_4 -257.23 79.50
βˆ_5 -3.21 1.42
βˆ_6 -2.42 0.92
βˆ_7 22.98 9.80
Table 7: Coefficient estimates for BRCAPRO + BCRAT (E2).
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C CGN Validation - Additional Tables
Variable N Age Affected 1st-degree Relatives Follow-up Censored Cases
(median [IQR]) (%) (median [IQR]) (%) (%)
Category 0 1 2+
BAYLOR 69 47 [38, 52] 34 (49.3) 28 (40.6) 7 (10.1) 7.5 [6.1, 8.6] 12 (17.4) 0 (0.0)
COLORADO 1198 51 [41, 64] 528 (44.1) 547 (45.7) 123 (10.3) 7.6 [6.4, 8.5] 85 (7.1) 23 (1.9)
DUKE 286 46 [38, 53] 134 (46.9) 116 (40.6) 36 (12.6) 7.2 [6.2, 8.2] 40 (14.0) 9 (3.1)
EMORY 136 44 [38.8, 51] 56 (41.2) 51 (37.5) 29 (21.3) 7.2 [6.6, 8.3] 29 (21.3) 3 (2.2)
GEORGETOWN 309 43 [35, 52] 107 (34.6) 147 (47.6) 55 (17.8) 7.8 [6.3, 8.5] 81 (26.2) 2 (0.6)
JH 469 47 [39, 56] 279 (59.5) 148 (31.6) 42 (9.0) 8.0 [6.1, 9.0] 73 (15.6) 10 (2.1)
MDAND 295 45 [37, 53] 215 (72.9) 64 (21.7) 16 (5.4) 6.1 [4.2, 7.0] 87 (29.5) 4 (1.4)
UCI 608 48 [37, 59] 352 (57.9) 223 (36.7) 33 (5.4) 5.3 [4.0, 7.1] 209 (34.4) 4 (0.7)
UNC 229 46 [39, 53] 80 (34.9) 111 (48.5) 38 (16.6) 8.0 [7.1, 9.0] 28 (12.2) 6 (2.6)
UNM 324 [41, 63] 160 (49.4) 123 (38.0) 41 (12.7) 6.6 [6.0, 7.5] 43 (13.3) 11 (3.4)
UPENN 540 45 [37, 53] 297 (55.0) 185 (34.3) 58 (10.7) 8.1 [6.6, 9.1] 76 (14.1) 8 (1.5)
UTAH 880 47 [35, 61] 522 (59.3) 298 (33.9) 60 (6.8) 7.3 [5.4, 8.0] 61 (6.9) 14 (1.6)
UTSA 92 43 [35.8, 52] 29 (31.5) 48 (52.2) 15 (16.3) 5.1 [4.0, 6.5] 36 (39.1) 1 (1.1)
UTSW 247 41 [33.5, 47] 88 (35.6) 116 (47.0) 43 (17.4) 6.6 [5.6, 7.6] 30 (12.1) 4 (1.6)
UWASH 1632 46 [37, 56] 1290 (79.0) 291 (17.8) 51 (3.1) 7.6 [6.9, 8.3] 44 (2.7) 13 (0.8)
Table 8: CGN cohort characteristics by center.
O/E C-statistic ∆BS ∆LS
Performance Metrics
B+B (M) 0.98 (0.84, 1.13) 0.68 (0.64, 0.71) 0.25 (-0.50, 0.95) 0.45 (-0.13, 0.96)
B+B (E) 1.08 (0.92, 1.23) 0.68 (0.63, 0.72) 0.35 (-0.22, 0.86)
BRCAPRO 1.25 (1.07, 1.43) 0.64 (0.60, 0.68) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.08 (0.92, 1.24) 0.67 (0.63, 0.71) 0.32 (-0.55, 1.12) -0.76 (-1.64, 0.11)
IBIS 0.93 (0.79, 1.07) 0.67 (0.63, 0.70) -0.08 (-0.88, 0.64)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E2) 0.641 0.421 0.331
B+B(M)>BRCAPRO 0.903 0.994 0.735 0.943
B+B(M)>BCRAT 0.648 0.642 0.383 0.988
B+B(M)>IBIS 0.707 0.749 0.822
B+B(E2)>BRCAPRO 0.970 0.998 0.887
B+B(E2)>BCRAT 0.579 0.710 0.569
B+B(E2)>IBIS 0.476 0.737 0.873
Table 9: Performance over follow-up period in entire CGN cohort. B+B: BRCAPRO+BCRAT. ∆BS:
% relative improvement in Brier Score compared to BRCAPRO. ∆LS: % relative improvement in
logarithmic score compared to BRCAPRO. The “Comparisons Across Bootstrap Replicates" section
shows pairwise comparisons involving the combination models across 1000 bootstrap replicates
of the validation dataset; the row for A > B shows the proportion of bootstrap replicates where
model A outperformed model B with respect to each metric. Proportions > 0.5 are highlighted in
blue (with darker shades of blue for higher proportions) and proportions ≤ 0.5 are highlighted in
red (with darker shades of red for lower proportions).
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O/E C-statistic ∆BS ∆LS
Strong Family History (45 cases)
Performance Metrics
B+B (M) 0.85 (0.62, 1.09) 0.67 (0.59, 0.75) -0.04 (-2.00, 1.54) 0.07 (-2.63, 2.15)
B+B (E) 1.10 (0.81, 1.41) 0.65 (0.57, 0.73) -0.10 (-1.37, 1.16)
BRCAPRO 1.40 (1.03, 1.81) 0.63 (0.54, 0.72) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.05 (0.77, 1.35) 0.61 (0.52, 0.70) -0.12 (-2.48, 2.00) -3.36 (-7.07, -0.29)
IBIS 0.77 (0.56, 0.98) 0.68 (0.59, 0.78) -0.75 (-3.14, 0.99)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E2) 0.385 0.930 0.522
B+B(M)>BRCAPRO 0.781 0.916 0.464 0.501
B+B(M)>BCRAT 0.322 0.963 0.525 0.943
B+B(M)>IBIS 0.954 0.321 0.808
B+B(E2)>BRCAPRO 0.933 0.685 0.420
B+B(E2)>BCRAT 0.336 0.953 0.534
B+B(E2)>IBIS 0.717 0.144 0.770
Less Family History (114 cases)
Performance Metrics
B+B (M) 1.18 (0.97, 1.39) 0.68 (0.63, 0.73) 0.54 (-0.06, 1.11) 0.53 (0.07, 1.06)
B+B (E) 1.17 (0.96, 1.38) 0.68 (0.64, 0.72) 0.59 (0.14, 1.07)
BRCAPRO 1.31 (1.08, 1.55) 0.63 (0.58, 0.68) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
BCRAT 1.20 (0.99, 1.42) 0.69 (0.65, 0.73) 0.65 (0.06, 1.26) -0.22 (-1.09, 0.50)
IBIS 1.14 (0.94, 1.35) 0.68 (0.64, 0.72) 0.31 (-0.22, 0.82)
Comparisons Across Bootstrap Replicates
B+B(M)>B+B(E2) 0.153 0.432 0.361
B+B(M)>BRCAPRO 0.990 0.991 0.954 0.992
B+B(M)>BCRAT 0.966 0.115 0.230 0.958
B+B(M)>IBIS 0.060 0.593 0.741
B+B(E2)>BRCAPRO 0.985 0.999 0.996
B+B(E2)>BCRAT 0.964 0.163 0.281
B+B(E2)>IBIS 0.062 0.603 0.844
Table 10: Performance over follow-up period in CGN cohort, stratified by family history (whether
or not the proband met the NCCN criteria for further genetic risk evaluation [63]; in applying
the criteria, we only used information on breast and ovarian cancer diagnoses in relatives). B+B:
BRCAPRO+BCRAT. ∆BS: % relative improvement in Brier Score compared to BRCAPRO. The
“Comparisons Across Bootstrap Replicates" section shows pairwise comparisons involving the
combination models across 1000 bootstrap replicates of the validation dataset; the row for A > B
shows the proportion of bootstrap replicates where model A outperformed model B with respect
to each metric. Proportions > 0.5 are highlighted in blue (with darker shades of blue for higher
proportions) and proportions ≤ 0.5 are highlighted in red (with darker shades of red for lower
proportions).
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